Haimei Xing

Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.

Søren B. Padkjær, B. Shan, Haisun Zhu, 2017, Journal of biotechnology.

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

J. Hou, Haimei Xing, Wei Jia, 2022, The Journal of biological chemistry.

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Zhiwei Wang, X. Liu, Xiaomin Song, 2019, Journal of medicinal chemistry.

Journal Pre-proof BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

Junjie Hou, Haimei Xing, Wei Jia, 2022 .

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.

Yuehua Wu, X. Liu, Shuaishuai Chen, 2023, Journal of medicinal chemistry.

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

R. Rosenquist, E. Thompson, A. Roberts, 2019, Blood.

Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.

L. Zheng, Shuaishuai Chen, L. Luo, 2018, European journal of medicinal chemistry.

Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models

Zhiwei Wang, X. Liu, Xiaomin Song, 2020 .